Gene therapy for restenosis: Getting nearer the heart of the matter

Circulation Research

Volumn 82, Issue 3, 1998, Pages 295-305

  Baek, Sanghong ^a   March, Keith L ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Richard L Roudeboush V A M C   (United States)

Author keywords

Gene therapy; Local delivery; Restenosis; Transduction efficiency; Vectors

Indexed keywords

GENE PRODUCT;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; CELL MIGRATION; CELL PROLIFERATION; CLONING VECTOR; CYTOSTASIS; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; IMMUNE RESPONSE; PRIORITY JOURNAL; RESTENOSIS; RETROVIRUS; REVIEW;

EID: 0032559627     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.82.3.295     Document Type: Review

References (122)

1. Nabel EG, Plautz G, Boyce FN, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science. 1989;244:1342-1344.
2. Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC. Implantation of vascular grafts lined with genetically modified endothelial cells. Science. 1989;244:1344-1346.
3. Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation. 1989;80:1347-1353.
4. Nabel EG, Shum L, Pompili VJ, Yang Z-Y, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel GJ. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA. 1993;90:10759-10763.
5. Nabel EG, Yang Z, Liptay S, San H, Gordon D, Haudenschild CC, Nabel GJ. Recombinant platelet-derived growth factor β gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest. 1993;91:1822-1829.
6. Nabel EG, Yang Z-Y, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature. 1993;362: 844-846.
7. DeYoung MB, Dichek DA. Gene therapy for restenosis: are we ready? Circ Res. 1998;82:306-313.
8. Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel EG, Pharmacek MS, Leiden JM. Cytostaric gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
9. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirusmediated overexpression of the cyclin/cyclin-dependent kinase inhibitor, p21, inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260-2268.
10. Aprelikova O, Xiong Y, Liu ET. Both p16 and p21 families of cyclindependent kinase (CDK) inhibitors block the phosphorylation of cyclindependent kinases by the CDK-activating kinase. J Biol Chem. 1995;270: 18195-18197.
11. Smith RC, Branellec D, Gorski DH, Guo K, Perlman H, Dedieu JF, Pastore C, Mahfoudi A, Denefle P, Isner JM, Walsh K. p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev. 1997;11:1674-1689.
12. Indolfi C, Awedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury m vivo. Nat Med. 1995;1:541-545.
13. Ueno H, Yamamoto H, Ito S, Li JJ, Takeshita A. Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler Thromb Vasc Biol 1997;17: 898-904.
14. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A. 1994;91: 10732-10736.
15. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 1994;265:781-784.
16. Simari RD, San H, Rekhter M, Ohno T, Gordon D, Nabel GJ, Nabel EG. Regulation of cellular proliferation and intimai formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest. 1996;98: 225-235.
17. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA. 1992; 89:33-37.
18. Harrell RL, Rajanayagam Sharmini MA, Masharn Doanes A, Guzman RJ, Hirschowitz EA, Crystal RG, Epstein SE, Finkel T. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation. 1997;96:621-627.
19. Crisby M, Kallin B, Thyberg J, Zhivotovsky B, Orrenius S, Kostulas V, Nilsson J. Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis. 1997;130,17-27.
20. Perlman H, Maillard L, Krasinski K, Walsh K. Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury, Circulation. 1997;95:981-987.
21. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 1996;94:1655-1664.
22. Shi Y, O'Brien JE Jr, Fard A, Zalewski A. Transforming growth factor-beta 1 expression and myofibroblast formation during arterial repair. Anterioscler Thromb Vasc Biol. 1996;16:1298-1305.
23. Shi Y, Pieniek M, Fard A, O'Brien J, Mannion JD, Zalewski A. Adventitial remodeling after coronary arterial injury. Circulation, 1996;93: 340-348.
24. Rutherford C, Martin W, Salame M, Carrier M, Anggard E, Ferns G. Substantial inhibition of neointimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. Atherosclerosis, 1997; 130:45-51.
25. Graf K, Xi XP, Yang D, Fleck E, Hsueh WA, Law RE. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension. 1997;29:334-339.
26. Donovan MJ, Miranda RC, Kraemer R, McCaffrey TA, Tessarollo L, Mahadeo D, Sharif S, Kaplan DR, Tsoulfas P, Parada L. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells: regulation of expression in response to injury. Am J Pathol. 1995;147:309-324.
27. Pepper MS, Montesano R, Mandriota SJ, Orci L, Vassalli JD. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein. 1996;49:138-162.
28. Mandriota SJ, Seghezzi G, Vassalli JD, Ferrara N, Wasi S, Mazzieri R, Mignatti P, Peper MS. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem. 1995;270:9709-9716.
29. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
30. Zempo N, Kenagy RD, Au YP, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg. 1994;20:209-217.
31. Hasenstab D, Forough R, Clowes AW. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. Circ Res. 1997;80:490-496.
32. Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell function in vitro and in vivo. Circ Res 1996;79:812-820.
33. Carmeliet P, Moons L, Dewerchin M, Mackman N, Luther T, Breier G, Ploplis V, Muller M, Nagy A, Plow E, Gerard R. Edging: insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci. 1997;811:191-206.
34. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 1997;99:200-208.
35. Dichek DA, Anderson J, Kelly AB, Hanson SR, Harker LA. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation. 1996;93:201-209.
36. Dunn PF, Newman KD, Jones M, Yamada I, Shayani V, Virmani R, Dichek DA. Seeding of vascular grafts with genetically modified endothelial cells: secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo. Circulation. 1996;93:1439-1446.
37. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviralmediated expression of recombinant hirudin reduces neointimal formation after arterial injury. Nat Med. 1996;2:293-298.
38. Clowes AW. Improving the interface between biomaterials and the blood: the gene therapy approach. Circulation, 1996;93:1319-1320.
39. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Pnc Natl Acad Sci U S A. 1995;92:1137-1141.
40. Varenne OH, Pislaru S, Gillijns H, Gerard RD, Van de Werf F, Collen D, Janssens SP. Adenoviral gene transfer of human constitutive endothelial nitric oxide synthase to injured coronary arteries. J Am Coll Cardiol. 1997;29:380A. Abstract.
41. Barath P, Popov A, Michiels R. Nipple balloon catheter. Semin Intervent Cardiol 1996;1:43.
42. Pavlides GS, Barath P, Maginas A, Vasilikos V, Cokkinos DV, O'Neil WW. Intramural drug delivery by direct injection within the arterial wall: first clinical experience with a novel intracoronary delivery-infiltrator system. Cathet Cardiovosc Diagn. 1997;41:287-292.
43. Zoldhelyi P, McNatt J, Xu X-M, Loose-Mitchell D, Meidell RS, Clubb FJJr, Buja LM, Willenon JT, Wu KK. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation. 1996;93:10-17.
44. Asahara T, Bauters C, Pastore C, Kearney M. Rossow S, Bunting S, Ferrara N, Synies JF, Isner JM. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimai hyperplasia in balloon-injured rat carotid artery. Circulation. 1995;91: 2793-2801.
45. Laitinen M, Zachary I, Breier G, Pakkanen T, Yla-Herttuala S. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther. 1997;8:1737-1744.
46. 165gene transfer. Circulation. 1996;94:3291-3302.
47. Van Belle E, Tio FO, Chen D, Maillard L, Chen D, Kearney M, Isner JM. Passivation of metallic stems after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimai thickening. J Am Coll Cardiol. 1997;29:1371-1379.
48. O'Brien ER, Alpers CE, Stewart DK, Ferguson M, Tran N, Gordon D, Benditt EP, Hinohara T, Simpson JB, Schwartz SM. Proliferation in primary and restenotic coronary atherectomy tissue: implications for antiproliferative therapy. Circ Res. 1993;73:223-231.
49. Kearney M, Pieczek A, Haley L, Losordo DW, Andres V, Schainfeld R, Rosenfield K, Isner JM. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation. 1997;95:1998-2002.
50. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong SC, Hong MK, Kovach JA, Leon MB. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996;94:35-43.
51. Di Mario C, Gil R, Camenzind E, Ozaki Y, von Birgelen C, Umans V, de Jaegere P, de Feyter PJ, Roelandt JRTC, Serruys PW. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol. 1995;75:772-777.
52. Simons M. Endogenous expression modification: antisense approaches. In: March KL, ed. Gene Transfer in the Cardiovascular System: Experimental Approaches and Therapeutic Implications. Boston, Mass/Dordrecht, Netherlands/London. UK: Kluwer Academic Publishers: 1997;6:143-175.
53. Flugelman MY, Jaklitsch MT, Newman KD, Casscells W, Bratthauer GL, Dichek DA. Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation. 1992;85:1110-1117.
54. Chapman GD, Lim CS, Gammon RS, Culp SC, Desper JS, Bauman RP, Swain JL, Stack RS. Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter. Circ Res. 1992;71:27-33.
55. Leclerc G, Gal D, Takeshita S, Nikol S, Weir L, Isner JM. Percutaneous arterial gene transfer in a rabbit model: efficiency in normal and balloon-dilated atherosclerotic arteries. J Clin Invest. 1992;90:936-944.
56. Takeshita S, Weir L, Chen D, Zheng LP, Riessen R, Bauten C, Symes JF, Ferrara N, Isner JM. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun. 1996;227:628-635.
57. 165 in patient with ischemic limb. Lancet. 1996;348:370-374.
58. Isner JM, Walsh K, Rosenfield K, Schainfeld R, Asahara T, Hogan K, Pieczek A. Arterial gene therapy for restenosis. Hum Gene Ther 1996;7: 989-1011.
59. Kreuzer J, Denger S, Reifers F, Beisel C, Haack K, Gebert J, Kubler W. Adenovirus-assisted lipofection: efficient in vitro gene transfer of luciferase and cytosine deaminase to human smooth muscle cells. Atherosclerosis. 1996;124:49-60.
60. Kupfer JM, Ruan XM, Liu G, Matloff J, Forrester J, Chaux A. High-efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine-DNA complexes. Hum Gene Ther. 1996;5:1437-1443.
61. Dzau VJ, Mann MJ, Morishita R, Kaneda Y, Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci U S A. 1996; 93:11421-11425.
62. Yang Y, Vanin EF, Whitt MA, Fornerod M, Zwart R, Schneiderman RD, Grosveld G, Nienhuis AW. Inducible, high-level production of infections murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum Gene Ther. 1995;6: 1203-1213.
63. Liu M-L, Winther DL, Kay MA. Pseudotransduction of hepatocytes by using concentrated pseudotyped vesicular stomatitis virus G glycoprotein (VSV-G)-Moloney murine leukemia virus-derived retrovirus vectors: comparison of VSV-G and amphotropic vectors for hepatic gene transfer. J Virol. 1996;70:2497-2502.
64. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A. 1996;93: 11400-11406.
65. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation. 1993;88:2838-2848.
66. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res. 1993;73:797-807.
67. Lemarchand P, Jones M, Yamada I, Crystal RG. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Rrs. 1993;72:1132-1138.
68. Rome JJ, Shayani V, Newnian KD, Farrell S, Lee SW, Virmani R, Dichek DA. Adenoviral vector-mediated gene transfer into sheep arteries using a double-balloon catheter. Hum Gene Ther. 1994;5:1249-1258.
69. French BA, Mazur W, Ali NM, Geske RS, Finnigan JP, Rodgers GP, Roberts R, Raizner AE. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation 1994; 90:2402-2413.
70. Schulick AH, Vassalli G, Dunn PF, Dong G, Rade JJ, Zamarron C, Dichek DA. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries: potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin. Invest. 1997;99: 202-219.
71. Gerszten RE, Luscinskas FW, Ding HT, Dichek DA, Stoolman LM, Gimbrone MA Jr, Rosenzweig A. Adhesion of memory lymphocytes to vascular cell adhesion molecule-1-transduced human vascular endothelial cells under simulated physiological flow conditions in vitro. Circ Res. 1996;79:1205-1215.
72. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, Libby P, Dichek DA. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest. 1995;96:2955-2965.
73. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y, Sato Y, Yokoi H, Hamasaki N, Nosaka H, et al. Three-year follow-up after implantation of metallic coronary-artery stems. N Engl J Med 1996; 334:561-566.
74. Yang Y, Ertl HCJ, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity, 1994;1:433-442.
75. Yang Y, Nunes FA, Berencsi K, Furth EE, Gînczîl E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy, Proc Natl Acad Sci U S A. 1994;91:4407-4411.
76. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med. 1996;2: 545-550.
77. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses detective in E2a. Hum Gene Ther. 1994;5:1217-1229.
78. Gorziglia MI, Kadan MJ, Yei S, Lim J, Lee GM, Luthra R, Trapnell BC. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol. 1996;70:4173-4178.
79. Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line and a system for construction of adenovirus vectors with El and E2a deleted. J Virol. 1996;70:7030-7038.
80. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 1996;70:8934-8943.
81. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol. 1996;70:6497-6501.
82. Yeh P, Dedieu JF, Orsini C, Vigne E, Denefle P, Perricaudet M. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996;70:559-565.
83. Kochanek S, Clemens PR, Mitani K, Chen H-H, Chan S, Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci U S A. 1996;93:5731-5736.
84. Fisher KJ, Choi H, Burda J, Chen S-J, Wilson JM. Recombinam adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology. 1996;217:11-22.
85. GuÇrette B, Vilquinn JT, Gingras M, Gravel C, Wood KJ, Tremblay JP. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum Gene Ther. 1996; 7:1455-1463.
86. Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 1996;273: 1862-1864.
87. Zsengeller ZK, Boivin GP, Sawchuk SS, Trapnell BC, Whitsett JA, Hirsch R. Anti-T cell receptor antibody prolongs transgene expression and reduces lung inflammation after adenovirus-mediated gene transfer. Hum Gene Ther. 1997;8:935-941.
88. Wickham TJ, Carrion ME, Kovesdi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther. 1995;2:750-756.
89. Witkham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I, Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol. 1996;70: 6831-6838.
90. Stevenson SC, McClelland A. Adenoviral gene delivery approaches for systemic expression. In: March KL, ed. Gene Transfer in the Cardiovascular System: Experimental Approaches and Therapeutic Implications. Boston, Mass/ Dordrecht, Netherlands/London, UK: Kluwer Academic Publishers: 1997;19:433-448.
91. Duan D, Fisher KJ, Burda JF, Engelhardt JF. Structural and functional heterogeneity of integrated recombinant AAV genomes, Virus Res. 1997; 48:41-56.
92. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A. 1996;93:14082-14087.
93. Gnatenko D, Arnold TE, Zolotukhin S, Nuovo GJ, Muzycka N, Bahou WF. Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells. J Invest Med. 1997;45: 87-98.
94. Lynch CM, Hara PS, Leonard JC, Williams JK, Dean RH, Geary RL. Adeno-associated vims vectors for vascular gene delivery. Circ Res. 1997; 80:497-505.
95. March KL. Methods of local gene delivery to vascular tissues. Semin Intervent Cardiol 1996;1:215-223.
96. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol. 1990;15:475-481.
97. Feldman LJ, Steg PG, Zheng LP, Chen D, Kearney M, McGarr SE, Barry JJ, Dedieu JF, Perricaudet M. Isner JM. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest. 1995;95:2662-2671.
98. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science. 1990;244:1285-1288.
99. Willard JE, Landau C, Glamann DB, Burns D. Jessen ME, Pirwitz MJ, Gerard RD, Meidell RS. Genetic modification of the vessel wall: comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus. Circulation. 1994;89:2190-2197.
100. March KL, Madison JE, Trapnell BC. Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implications for cardiovascular gene therapy. Hum Gene Ther. 1995;6:41-53.
101. March KL, Gradus-Pizlo I, Wilensky RL, Yei S, Trapnell BC. Cardiovascular gene therapy using adenoviral vectors: distant transduction following local delivery using a porous balloon catheter. J Am Cell Cardiol. 1994;23:117A. Abstract.
102. Wilensky RL, March KL, Gradus-Pizlo I, Schauwecker MM, Robinson J, Carbon K, Hathaway DR. Regional and arterial localization of radioactive microparticles following local delivery using unsupported or supported porous balloon catheters. Am Heart J. 1995;129:852-859.
103. Feldman LJ, Pastore CJ, Aubailly N, Kearney M, Chen D, Perricaudet M, Steg PG, Isner JM. Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors. Gene Ther. 1997;4: 189-198.
104. Landau C, Pirwitz MJ, Willard MA. Gerard RD, Meidell RS, Willard SE. Adenoviral mediated gene transfer to atherosclerotic arteries after balloon angioplasty. Am Heart J. 1995;129:1051-1057.
105. Tahlil O, Brami M, Feldman LJ, Branellec D, Steg PG. The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res. 1997; 33:181-187.
106. Nunes GL, Hanson SR, King SB III, Sahatjian RZ, Scott NA, Local delivery of a synthetic antithrombin with a hydrogel-coated angioplasty balloon catheter inhibits platelet-dependent thrombosis. J Am Coll Cardiol. 1994;23:1578-1583.
107. Steg PG, Feldman LJ, Scoazec JY, Tahlil O, BarryJJ, Boulechfar S, Ragot T, Isner JM, Perricaudet M. Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation. 1994;90:1648-1656.
108. Reissen R, Rahimizadeh H, Blessing E, Takeshita S, Barry JJ, Isner JM. Arterial gene transfer using pure DNA applied directly to a hydrogelcoated angioplasty balloon. Hum Gene Ther. 1993;4:749-758.
109. Femandez-Ortiz A, Meyer BJ, Mailhac A, Falk E, Badimon L, Fallon JT, Fuster V, Chesebro JH, Badimon JJ. A new approach to local intravascular drug delivery: iontophorectic balloon. Circulation. 1994;89:1518-1522.
110. Gonschior P, Pahl C, Huehens TY, Gerheuser F, Erdemci A, Larisch K, Dellian M, Deil S, Goetz A, Lehr HA, Hofling B. Comparison of local intravascular drug-delivery catheter systems. Am Heart J. 1995;130: 1174-1181.
111. Mehdi K, Wilensky RL, Baek SH, Trapnell BC, March KL. Efficient adenovirus-mediated perivascular gene transfer and protein delivery by a transvascular injection catheter. J Am Coll Cardiol. 1996;27:164A. Abstract.
112. Rios CD, Ooboshi H, Piegors D, Davidson BL, Heistad DD. Adenovirus-mediated gene transfer to normal and atherosclerotic arteries: a novel approach. Arterioscler Thromb Vasc Biol. 1995;15:2241-2245.
113. Woody M, Mehdi K, Zipes DP, Brantley M, Trapnell BL, March KL. High efficiency adenovirus-mediated pericardial gene transfer in vivo. J Am Coll Cardiol 1996;27:31A. Abstract.
114. Lamping KG, Rios CD, Chun JA, Ooboshi H, Davidson BL, Heistad DD. Interpericardial administration of adenovirus for gene transfer. Am J Physiol. 1997;272:H31U-H317.
115. Gradus-Pizlo I, Wilensky RL, March KL, Fineberg N, Michaels M, Sandusky GE, Hathaway DR. Local delivery of biodegradable microparticles containing colchicine analogue: effects on restenosis and implications for catheter-based drug delivery. J Am Coll Cardiol. 1995;26: 1549-1557.
116. Muller DWM, Topol EJ, Abrams GD, Gallagher KP, Ellis SG. Intramural methotrexate therapy for the prevention of neointimal thickening after balloon angioplasty. J Am Coll Cardiol. 1992;20:460-466.
117. Mittereder N, March KL, Trapnell B, Evaluation of the concentration and bioactivity of adenoviral vectors for gene therapy. J Virol. 1996;70: 7498-7509.
118. March KL, Trapnell B. Phamiacokinetics of local vector delivery to vascular tissues: implications for efficiency and localization. In: March KL, ed. Gene Transfer in the Cardiovascular System: Experimental Approaches and Therapeutic Implications. Boston, Mass/Dordrecht, Netherlands/London, UK: Kluwer Academic Publishers; 1997;21:477-498.
119. Wilensky RL, March KL, Gradus-Pizlo I, Sandusky G, Hathaway DR. Vascular injury, repair, and restenosis following percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation, 1995;92:2995-3005.
120. Farb A, Virmani R, Dichek DA. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall: modeling with microscopic tracer particles and verification with a recombinant adenoviral vector. Arterioscler Thromb, 1994;14:148-161.
121. Nasser TK, Mehdi K, Wilensky RL, March KL. Microparticle deposition in periarterial microvasculature and intramural dissections after porous balloon delivery into atherosclerotic vessels: quantication and localization by confocal scanning laser microscopy. Am Heart J. 1996;131:892-898.
122. Maillard L, Ziol M, LeFeuvre C, Tahlil O, Feldman LJ, Branellec D, Perricaudet M, Steg PG. Improved efficiency of percutaneous adenoviral-mediated arterial gene transfer by pre-treatment with elastase. J Am Coll Cardiol. 1996;27:225A. Abstract.